Insmed Incorporated (NASDAQ:INSM) Receives $94.00 Average PT from Analysts

Shares of Insmed Incorporated (NASDAQ:INSM) have been given an average recommendation of “Buy” by the sixteen ratings firms that are presently covering the company, MarketBeat Ratings reports. Sixteen research analysts have rated the stock with a buy rating. The average 1-year price objective among brokerages that have covered the stock in the last year is $94.00.

A number of brokerages recently issued reports on INSM. Royal Bank of Canada restated an “outperform” rating and set a $100.00 price target on shares of Insmed in a report on Wednesday, March 19th. Truist Financial boosted their target price on Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Wells Fargo & Company raised their price target on Insmed from $85.00 to $107.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 19th. JPMorgan Chase & Co. boosted their price objective on shares of Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a research report on Friday, February 7th. Finally, HC Wainwright restated a “buy” rating and issued a $90.00 price objective on shares of Insmed in a report on Friday, February 21st.

Insmed Stock Performance

NASDAQ:INSM opened at $77.69 on Friday. The company has a debt-to-equity ratio of 2.03, a quick ratio of 5.99 and a current ratio of 6.37. Insmed has a fifty-two week low of $21.92 and a fifty-two week high of $84.91. The firm has a market cap of $14.06 billion, a PE ratio of -13.90 and a beta of 1.28. The business has a 50 day moving average price of $78.07 and a 200-day moving average price of $73.93.

Insmed (NASDAQ:INSM) last announced its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The firm had revenue of $104.44 million for the quarter, compared to analysts’ expectations of $102.31 million. Equities research analysts predict that Insmed will post -4.56 earnings per share for the current year.

Insiders Place Their Bets

In other news, insider Martina M.D. Flammer sold 6,172 shares of the firm’s stock in a transaction on Friday, January 10th. The stock was sold at an average price of $63.64, for a total value of $392,786.08. Following the transaction, the insider now directly owns 101,549 shares in the company, valued at $6,462,578.36. This trade represents a 5.73 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO William Lewis sold 2,978 shares of the firm’s stock in a transaction dated Friday, January 10th. The stock was sold at an average price of $63.36, for a total value of $188,686.08. Following the completion of the transaction, the chief executive officer now directly owns 392,589 shares in the company, valued at $24,874,439.04. The trade was a 0.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 550,957 shares of company stock valued at $42,992,528. 4.60% of the stock is owned by insiders.

Hedge Funds Weigh In On Insmed

A number of institutional investors and hedge funds have recently made changes to their positions in the business. California State Teachers Retirement System increased its position in Insmed by 4.5% in the fourth quarter. California State Teachers Retirement System now owns 153,343 shares of the biopharmaceutical company’s stock worth $10,587,000 after buying an additional 6,601 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its stake in Insmed by 10.5% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 3,231 shares of the biopharmaceutical company’s stock worth $223,000 after acquiring an additional 307 shares during the period. Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in Insmed during the 4th quarter worth approximately $6,798,000. Mackenzie Financial Corp lifted its holdings in Insmed by 12.5% during the fourth quarter. Mackenzie Financial Corp now owns 10,883 shares of the biopharmaceutical company’s stock valued at $751,000 after purchasing an additional 1,213 shares in the last quarter. Finally, GF Fund Management CO. LTD. bought a new position in shares of Insmed in the fourth quarter worth approximately $259,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.